Raymond James & Associates’s Lipocine LPCN Stock Holding History

Raymond James & Associates’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-641	Closed	-$9K	–	4063
2022 Q2	$9K	Buy	+641	New	+$9.99K	﹤0.01%	3942

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raymond James & Associates's LPCN Position: Q3 2022 in Review

Raymond James & Associates sold out of Lipocine (LPCN) in Q3 2022, closing a stake of 641 shares — an estimated $9K sold.

Raymond James & Associates first reported a position in LPCN in Q2 2022 and held it in 1 quarter. The position peaked at $9K in Q2 2022. 46 funds tracked by Wall St. Rank hold LPCN as of Q3 2022.

Raymond James & Associates reported no remaining Lipocine position as of Q3 2022 after selling out during the quarter.
Raymond James & Associates sold 641 Lipocine shares in Q3 2022, an estimated $9K.
Raymond James & Associates first reported a position in Lipocine in Q2 2022 and held it in 1 quarter.
Raymond James & Associates's Lipocine position peaked at $9K in Q2 2022.
46 funds tracked by Wall St. Rank held Lipocine as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.